Everyone Thinks the Eli Lilly Story Is Played Out. Cramer Thinks They're Dead Wrong

Eli Lilly (LLY) rebounded, rallying 2.63% after Jim Cramer pushed back on the “Mounjaro is played out” narrative and cited a JPMorgan note highlighting potential upside from Mounjaro international. The bull case rests on rapid international growth (Mounjaro Q1 2026 revenue $8.66B, +125% Y/Y; international revenue +81% with China reimbursement) and an oral GLP-1 launch angle (Foundayo approved; Cramer calls it “radical”), with a further catalyst in early August earnings. Ahead of the first-week-of-August report, management raised 2026 guidance to $82.0–$85.0B revenue and $35.50–$37.00 non-GAAP EPS, but the setup risk is asymmetric if oral prescriptions and net pricing from rebate/market-access deals disappoint.

Analysis

The selloff looks more like positioning damage than a change in fundamentals: when a crowded winner gets de-rated, the market initially prices in margin decay faster than the underlying volume curve. For LLY, the real lever is not whether GLP-1 demand is “over,” but whether the next leg of growth comes from lower-friction channels — international reimbursement, oral access, and broader prescriber willingness — which can support revenue growth even if per-script economics soften. That means the stock’s near-term multiple is hostage to proof points, but the 6-18 month setup still favors the category leader if execution stays ahead of reimbursement-driven competition.

The second-order winner is the company with the best ability to turn a biologic-heavy category into a broader access model; the loser is the rival forced to defend share with rebates, which usually compresses industry-wide net pricing before volume offsets arrive. If the market starts believing oral GLP-1 is a true access expansion, then the competitive moat shifts from pure efficacy to distribution, adherence, and physician trust — a setup that can widen share gaps even if headline efficacy differences narrow. That also implies the first real risk isn’t generic competition; it’s a slower-than-modeled uptake curve that would expose how much of the current earnings power is already discounted.

Into early August, the setup is binary: strong international/obesity uptake can justify the premium multiple; a miss on launch cadence or guidance would likely trigger a sharp de-rating because expectations are elevated and the stock has little valuation cushion. The contrarian angle is that investors may be underestimating how much the category is still in first-penetration mode globally, but overestimating how quickly those users convert into clean margin expansion. In other words, the long-term thesis is likely intact while the next 4-8 weeks are mostly about whether the market gets another reason to pay up now or waits for proof after the print.

Key Decisions for Investors

• Buy LLY on post-rotation weakness only if it holds above the prior week’s breakout area; 1-3 month view is positive, but avoid chasing after a multi-day rebound because the August print can still reset the multiple. Best expression: small starter long with a defined stop if management signals slower oral or international uptake.
• Use a bull call spread in LLY into the first week of August to capture upside from a clean beat without paying full implied volatility; this is the cleaner expression if you think the stock is underappreciated but near-term headline risk remains high.
• Pair trade: long LLY / short NVO for the next 4-12 weeks if you believe rebate pressure will continue to hit the weaker competitor harder than the market expects. Falsifier: evidence that NVO stabilizes share without further discounting, or that LLY’s net pricing deteriorates faster than volume grows.
• For existing LLY holders, hedge event risk with a short-dated put spread into earnings rather than trimming core exposure; the risk/reward is asymmetrical because a guide miss can compress multiple and EPS simultaneously.
• Watch item, not a trade yet: if JPM’s view is confirmed by other sell-side notes and channel checks, the obesity complex should outperform the broader pharma group (e.g. XLV) over 1-3 months; if not, the recent move is likely just a crowded-trade unwind rather than a durable re-rating.